Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Arimidex anastrozole: Additional Phase III data

After a median follow-up of 100 months, additional data from the Phase III ATAC trial

Read the full 156 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE